Details

Autor(en) / Beteiligte

• Tao, Shan-Dong
• Song, Li-Xiao
• Deng, Yuan
• Chen, Yue
• Zhang, Xin
• Ding, Bang-He
• Wang, Chun-Ling
• Yu, Liang

Titel

Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia

Ist Teil von

• Zhongguo shi yan xue ye xue za zhi, 2023-06, Vol.31 (3), p.677

Ort / Verlag

China

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To observe the efficacy and safety of CLAE intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed/refractory acute leukemia (R/R AL). CLAE regimen [cladribine 5 mg/(m ·d), d 1-5; cytarabine 1.5 g/(m ·d), d 1-5; etoposide 100 mg/(m ·d), d 3-5] followed by allo-HSCT was used to treat 3 R/R AL patients. The patients received CLAE chemotherapy in relapsed or refractory status and underwent bone marrow puncture to judge myelodysplastic state. After an interval of 3 to 5 days, followed by preconditioning regimen for allo-HSCT [fludarabine 30 mg/(m ·d), d -7 to d -3; busulfan 0.8 mg/kg q6h, d -6 to d -3 or d -5 to d -2. If the bone marrow hyperplasia was not active and the blasts were less than 10%, busulfan should be used for 3 days. If the bone marrow hyperplasia was active and the blasts were more than 10%, busulfan should be used for 4 days]. Cyclosporin A, mycophenolate mofetil and short-term methotrexate were used for graft-versus-host diseas